Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
jRCT2041230022Phase 3Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Aug 2023
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) comparing Pegcetacoplan with Placebo / Pegcetacoplan in OLE (2 arms). Started Aug 2023; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on jRCT2041230022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230022.